Why was the new diphtheria-containing infant vaccine delayed until at least 2021?
The delay for the new diphtheria-containing infant vaccine was not about safety but about when the product could be manufactured and distributed. This specific combination shot protects against diphtheria, tetanus, whooping cough, polio, Haemophilus influenzae type b, and hepatitis B. Although it received official approval, it would not reach pharmacies before 2021.
What the research says
The primary reason for the wait was that the new 6-in-1 infant vaccine was licensed but availability was delayed until at least 2021 3. This delay likely involved the time needed to scale up production and ensure the supply chain could meet demand for a new combination product.
Other sources discuss diphtheria in the context of different vaccines and age groups, which helps clarify the specific nature of the delay. For example, recommendations for adults have been updated to allow flexibility in using Tdap or Td vaccines for tetanus boosters 2. These updates show that while diphtheria protection is important, the specific infant combination vaccine faced unique logistical hurdles. Similarly, coverage data for other vaccines like Tdap and influenza among pregnant women highlights how vaccination schedules and product availability are monitored closely 1.
What to ask your doctor
- Will my child be able to receive the new 6-in-1 vaccine that includes diphtheria protection before 2021?
This question is drawn from common patient questions about Pediatrics and answered using cited medical research. We do not provide individualized advice.